CN113262391A

CN113262391A - Skin tightening micro-needle patch

Info

Publication number: CN113262391A
Application number: CN202110536415.0A
Authority: CN
Inventors: 张显玉; 顾宇灵; 王涛; 武欣越; 庞达
Original assignee: Shanghai Tianyin Biotechnology Co ltd; Harbin Medical University
Current assignee: Shanghai Tianyin Biotechnology Co ltd; Harbin Engineering University; Harbin Medical University
Priority date: 2021-05-17
Filing date: 2021-05-17
Publication date: 2021-08-17

Abstract

The invention relates to a skin-tightening microneedle patch which is characterized in that: the micro-needle base layer, the pore gel layer and the top layer are sequentially and fixedly connected in a superposed mode, the micro-needle array is arranged at the bottom end of the micro-needle base layer, the pore gel layer and the micro-needle array are integrally formed by degradable gel, slow-release medicines are added into the degradable gel, the slow-release medicines are stored in the pore gel layer, a controllable shrinkage layer can be arranged in the top layer, the controllable shrinkage layer is connected with a driver, the power supply of the driver is started to enable the controllable shrinkage layer to shrink, the power supply of the driver is turned off to enable the controllable shrinkage layer to recover to an initial state, the skin can be fixed, the medicines can be slowly released into the skin, the skin is prevented from being loosened by combining the mechanical effect on the skin, and the skin is promoted to be compact.

Description

Skin tightening micro-needle patch

Technical Field

The invention relates to a skin tightening microneedle patch.

Background

Safe, efficient, and controlled delivery of drugs to the human tissue system has been a major concern, and the most common delivery methods in the medical procedure today are oral administration and injection administration. On one hand, the medicine needs to pass through tissues and organs such as gastrointestinal tract, liver and the like in the oral administration technology, and on the other hand, the inactivation of the gastrointestinal tract and the first pass effect of the liver can metabolize part of the medicine so as to reduce the bioavailability of the medicine; on the other hand, some drugs can cause adverse stimulation to the gastrointestinal tract, thereby limiting the application range of oral administration, and being particularly not suitable for the transmission of polyembryony and protein drugs such as insulin and the like. Although the injection administration technology overcomes the defects, the ordinary needle with larger size is penetrated into human tissues to cause considerable pain, the compliance of patients is poor, and the operation of professionals is needed.

The percutaneous administration technology can overcome the defects of oral administration and injection administration, and the medicine applied on the surface of the skin directly enters the blood circulation of a human body after being absorbed by subcutaneous capillaries and reaches effective blood concentration so as to realize disease treatment.

The stratum corneum is the main barrier to transdermal penetration of drugs, and therefore, drugs applied to the skin surface do not sufficiently penetrate the skin. The transdermal drug delivery has the defects that the transdermal drug delivery dose is small, the drug delivery efficiency is low, the drug delivery varieties are limited and the like due to the fact that the stratum corneum which consists of dead skin cells can seriously obstruct the transdermal penetration of drugs and macromolecular drugs can hardly penetrate through the skin when the skin is used as a transmission medium for transdermal drug delivery, and the outermost thickness of the skin is 10-20 microns. In order to improve the transdermal drug delivery efficiency and expand the variety of transdermal drug delivery, researchers are continuously researching the improvement method of transdermal drug delivery technology from the aspects of chemistry and physical and mechanical biology, such as a chemical method using various transdermal enhancers, and physical methods such as iontophoresis, ultrasonic introduction, electroporation, and ultrasonic velocity injection of micro powder, etc., however, the improvement of transdermal drug delivery efficiency by the above technology and method is still limited.

The microneedle has the advantage of being capable of puncturing the stratum corneum, the barrier function of the stratum corneum is a key problem for limiting the transdermal drug delivery technology, the microneedle is used for locally destroying the stratum corneum of the skin, and micron-sized drug delivery microchannels are formed on the surface layer of the skin transiently, so that the transdermal drug delivery efficiency is remarkably improved, and the types of the drugs for transdermal drug delivery can be remarkably increased. In addition, because the micro-needle has very small size, the micro-needle can only puncture the horny layer of the skin without nerves and does not touch the deep tissue of the skin rich in nerves and blood vessels, so the pain feeling and the wound generated in the puncturing process are far smaller than those generated in the traditional injection administration, and the painless, non-invasive or minimally invasive administration is realized. If combined with other microfluid control systems, the micro-needle can also realize long-acting controllable drug delivery. After special design, the micro-needle can be combined with a corresponding micro-fluid control and analysis system, and can also be used for painless micro-biochemical sampling analysis of a human body. Vaccination is also one of the most promising fields of application of microneedles, since the presence of immunogenic cells in the skin can enhance the immune response of the body.

Disclosure of Invention

The invention provides a skin-tightening microneedle patch which can fix skin, slowly release medicines into the skin, periodically stimulate the skin, avoid skin relaxation and promote skin tightening.

In order to achieve the purpose, the invention adopts the technical scheme that:

a skin tightening microneedle patch is characterized in that: the micro-needle base layer, the pore gel layer and the top layer are sequentially overlapped and fixedly connected, a micro-needle array is arranged at the bottom end of the micro-needle base layer, the pore gel layer and the micro-needle array are integrally formed by degradable gel, slow-release medicines are added into the degradable gel, and the pore gel layer is used for storing the slow-release medicines;

can set up controllable shrink layer in the top layer, controllable shrink layer is the electrical shrinkage material, controllable shrink layer is connected with the driver electricity, the driver is opened, supplies controllable shrink layer shrink, the driver is closed, controllable shrink layer resumes initial state, and gel layer and micropin basic unit are driven by the subsidiary together in this in-process.

The firming skin microneedle patch, wherein: the controllable contraction layer is opened by the driver, the inward contraction of the controllable contraction layer is reduced, the driver is closed, the controllable contraction layer (4) is recovered to be in an initial state, the gel layer and the microneedle base layer are driven together in the process, and the driving mode is electric driving, air pressure driving and negative pressure driving.

The firming skin microneedle patch, wherein: the microneedle array is used for penetrating into the skin and slowly releasing the drug through the degradation reaction of the degradable gel.

The invention has the beneficial effects that: can fix skin, slowly release medicine into skin, prevent skin relaxation, and promote skin tightness.

Drawings

Fig. 1 is a structural view of a microneedle patch for tightening skin.

Fig. 2 is a structural diagram of the top layer of the tight skin micro-needle patch connected with a power supply.

Fig. 3 is a structure diagram of a controlled shrinkage layer of a tight skin microneedle patch in a shrinkage state.

Fig. 4 is a structural diagram of the controllable shrinkage layer of the tight skin micro-needle patch in an initial state.

Description of reference numerals: 1-microneedle base layer; 2-a layer of porous gel; 3-a top layer; 4-a controlled shrinkage layer; 5-microneedle array.

Detailed Description

As shown in fig. 1 to 4, the skin tightening microneedle patch is characterized in that: microneedle base layer 1, pore gel layer 2 and top layer 3 superpose fixed connection in proper order, the bottom of microneedle base layer 1 is equipped with microneedle array 5, microneedle base layer 1 pore gel layer 2 reaches microneedle array 5 is by degradable gel integrated into one piece, add the slowly-releasing medicine in the degradable gel, be used for storing the slowly-releasing medicine in the pore gel layer 2, microneedle array 5 supplies to pierce skin, through the degradation reaction of degradable gel is with the medicine slowly-releasing.

Can set up controllable shrink layer 4 in the top layer 3, controllable shrink layer 4 is the electrical shrinkage material, controllable shrink layer 4 is connected with the driver electricity, the driver is opened, supplies controllable shrink layer 4 shrink, the driver is closed, controllable shrink layer 4 resumes initial state, and this in-process gel layer and micropin basic unit are by the subsidiary drive together, and the drive mode is electric drive, atmospheric pressure and negative pressure drive.

In the embodiment, the bottom end of the microneedle base layer 1 is provided with the microneedle array 5, the microneedle base layer 1, the pore gel layer 2 and the microneedle array 5 are integrally formed by degradable gel, slow-release drugs are added into the degradable gel, the pore gel layer 2 is used for storing more needed slow-release drugs, the microneedle array 5 is used for penetrating into the skin and fixing, and the drugs are slowly released to deep tissues of the skin in the degradation process of the degradable gel.

The elasticity ratio of degradable gel is great, causes long-time extension easily, produces lax, then can set up in the top layer 3 controllable shrink layer 4, controllable shrink layer 4 with the power electricity is connected, when the power is opened, controllable shrink layer 4 is to the shrink of centre of a circle department, when the power is closed, controllable shrink layer 4 resumes initial condition, controllable shrink layer 4 utilizes controllable shrink layer 4 is the characteristic of electrical contraction material, through shrink and resume initial condition, promotes skin compactness, avoids skin lax.

The slow-release medicine added into the degradable gel comprises timolol, botulinum toxin type A, hyaluronic acid, collagen fibers, vitamin C and vitamin B.

Timolol is a beta receptor blocker, and is mainly applied to the treatment of neonatal hemangioma by plastic cosmetology department, and can selectively destroy vascular endothelial cells in the hemangioma so as to atrophy the hemangioma. The current main application method is the local wet application of timolol or external ointment preparation, and has the advantages of simple use and extremely low absorption efficiency and needs to be repeatedly used for a long time. After the degradable microneedle injection system is used, the drug can be uniformly injected into a hemangioma body at a low concentration, so that the atrophy and absorption of the hemangioma of a newborn are promoted.

Botulinum toxin type A is the most commonly used drug in plastic surgery and has a primary mechanism of action by blocking acetylcholine receptor signaling, which affects both neuromuscular junctions, sweat glands and sebaceous glands. Is mainly used for improving dynamic wrinkles of upper part, inhibiting secretion function of sweat gland and sebaceous gland (improving bromhidrosis, hyperhidrosis and acne), and improving muscle contour (face, shoulder and leg slimming). The traditional injection method is easy to have some obvious adverse reactions when the injection dosage is large at some positions, for example, the eyebrow droop appears when the injection position at the forehead is too low, so that the micro-drop injection method is required, the operation technical requirement of a doctor is very high, and the doctor is difficult to master skillfully. After the micro needle device is applied, botulinum toxin with different concentrations can be accurately injected into a preset area to achieve the aim of accurate injection, and the micro needle device can be applied to botulinum toxin injection of lower forehead skin, middle face inhibition of sebaceous gland function, facial fine lines and acne improvement, and axillary region injection to improve bromhidrosis and hyperhidrosis.

Hyaluronic acid is an important natural skin moisturizing factor, and can effectively combine water molecules in the skin, keep the skin in a moisturizing state and improve the skin barrier function. The current methods comprise methods such as external facial masks and intradermal water light injection, hyaluronic acid of the external facial masks cannot pass through skin barriers and can only act on the surface of the skin for a short time, and the pain of local water light injection is obvious. By applying the novel microneedle injection technology, the medicine can be accurately injected into the required skin layers under slight pain, and the skin hydration condition is effectively improved.

Collagen fibers are important extracellular matrixes in skin, play an important role in the aspects of skin result shaping and skin physiological functions, and the defects of the collagen fibers can cause the problems of local skin depression, poor skin texture and the like. The macromolecular collagen of the external facial mask cannot penetrate the skin barrier, and the local injection can only be used for local filling treatment at present and cannot realize low-concentration water light injection. The novel microneedle injection system can be used for uniformly injecting low-concentration collagen into dermal tissue and improving a cell support system.

Vitamin C and vitamin b have important functions in skin pigment metabolism and collagen fiber synthesis, the effective concentration of the vitamin C and vitamin b which can reach the dermis layer through external use or oral administration and intravenous injection is very low, and the requirement of the water light injection method on the operation level of doctors is very high. The novel microneedle injection system can be used for accurately injecting the medicine.

The plastic degradable micro-needle can be made of PPDO (poly phenylene sulfide) or PCL (polycaprolactone), PLLA (poly lactic acid) and other materials which are widely applied to the wire carving suspension wire material, and the action mechanism of the materials is to stimulate the synthesis of collagen fibers in the skin and improve the skin state.

The invention has the advantages that:

can fix skin, slowly release medicine into skin, prevent skin relaxation, and promote skin tightness.

The foregoing description is intended to be illustrative rather than limiting, and it will be appreciated by those skilled in the art that many modifications, variations or equivalents may be made without departing from the spirit and scope of the invention as defined in the appended claims.

Claims

1. A skin tightening microneedle patch is characterized in that: the micro-needle base layer (1), the pore gel layer (2) and the top layer (3) are sequentially overlapped and fixedly connected, a micro-needle array (5) is arranged at the bottom end of the micro-needle base layer (1), the pore gel layer (2) and the micro-needle array (5) are integrally formed by degradable gel, slow-release medicines are added into the degradable gel, and the pore gel layer (2) is used for storing the slow-release medicines;

can set up controllable shrink layer (4) in top layer (3), controllable shrink layer (4) are the electrical shrinkage material, controllable shrink layer (4) are connected with the driver electricity, the driver is opened, supplies controllable shrink layer (4) shrink, the driver is closed, initial state is resumed in controllable shrink layer (4), and this in-process gel layer and micropin basic unit are driven by the subsidiary together.

2. The tight skin microneedle patch according to claim 1, wherein: the controllable contraction layer (4) is opened, the controllable contraction layer (4) contracts inwards to be reduced, the driver is closed, the controllable contraction layer (4) recovers to the initial state, the gel layer and the microneedle base layer are driven together in the process, and the driving mode is electric driving, air pressure driving and negative pressure driving.

3. The tight skin microneedle patch according to claim 1, wherein: the microneedle array (5) is used for penetrating into the skin and slowly releasing the drug through the degradation reaction of the degradable gel.